Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A method for inhibiting inflammation in a subject which comprises administering to the subject a compound selected from the group consisting of~~: an anti-EN-RAGE antibody or fragment thereof and the V-domain of soluble RAGE polypeptide or fragment thereof~~ (i) an anti-EN-RAGE antibody, (ii) an EN-RAGE-binding fragment of an anti-EN-RAGE antibody, (iii) the V-domain of soluble RAGE polypeptide or (iv) an EN-RAGE-binding fragment of the V-domain of soluble RAGE polypeptide, thereby inhibiting inflammation in the subject.

2. (Canceled)

3. (Currently Amended) The method of claim 1, wherein the inflammation is ~~assoicated~~ associated with delayed hypersensitivity, accelerated atherosclerosis, or lupus nephritis.

4. (Previously Presented) The method of claim 1, wherein the subject is a human, a primate, a mouse, a rat or a dog.

5. (Previously Presented) The method of claim 1, wherein the administration comprises intralesional, intraperitoneal, intramuscular or intravenous injection; infusion; liposome-mediated delivery; or topical, intrathecal, per rectum,

gingival pocket, intrabronchial, nasal, oral, ocular or otic delivery.

6. (Previously Presented) The method of claim 1, wherein the compound is administered hourly, daily, weekly, monthly or annually.

7. (Previously Presented) The method of claim 1, wherein the effective amount of the compound comprises from about 0.000001 mg/kg body weight to about 100 mg/kg body weight.

8. (Previously Presented) The method of claim 1, wherein the subject is suffering from systemic lupus erythematosus, inflammatory lupus nephritis, septic shock or endotoxemia.

9. (Previously Presented) The method of claim 1, further comprising administering to the subject a pharmaceutically acceptable carrier during the administration of the compound.

10. (Previously Presented) The method of claim 9, wherein the carrier comprises a diluent.

11. (Currently Amended) The method of claim 9, wherein the carrier comprises[[,]] a virus, a liposome, a microencapsule, a polymer encapsulated cell or a retroviral vector.

12. (Previously Presented) The method of claim 9, wherein the carrier is an aerosol, intravenous, oral or topical carrier.

13. (Previously Presented) The method of claim 9, wherein the

compound is administered from a time release implant.

14. (Previously Presented) The method of claim 1, wherein the subject is suffering from an autoimmune or inflammatory disorder in which the recruitment of EN-RAGE-containing inflammatory cells occurs.

15. (Previously Presented) The method of claim 1, wherein the subject is suffering from a bacterial-associated or other pathogen-associated infection.

16. (Previously Presented) The method of claim 1, wherein the antibody is a monoclonal antibody or a polyclonal antibody.

17. (Previously Presented) The method of claim 1, wherein the antibody is a chimeric antibody, a humanized antibody or a primatized antibody.

18. (New) The method of claim 1, wherein the compound is an anti-EN-RAGE antibody.

19. (New) The method of claim 1, wherein the compound is an EN-RAGE-binding fragment of an anti-EN-RAGE antibody.

20. (New) The method of claim 1, wherein the compound is the V-domain of soluble RAGE polypeptide.

21. (New) The method of claim 1, wherein the compound is an EN-RAGE-binding fragment of the V-domain of soluble RAGE polypeptide.